Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614653 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00614653: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00614653 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00614653, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- RADIATION Radiation Therapy
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00614653
The ClinicalTrials.gov registry entry for NCT00614653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00614653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00614653 about?
NCT00614653 is a clinical study titled "Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer". The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
What is the current status of trial NCT00614653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT00614653?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Radiation Therapy (RADIATION), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00614653?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.